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Statins Downregulate K6a Promoter Activity:
A Possible Therapeutic Avenue for
Pachyonychia Congenita
Yiwei Zhao1, Ulrike Gartner1, Frances J.D. Smith1 and W.H. Irwin McLean1
Pachyonychia congenita (PC) is a keratinizing disorder predominantly caused by mutations in keratin 6a (K6a)
(B50% of cases) or K6b, K16, or K17. One means of treating PC is identification of small-molecule inhibitors of
PC-related keratins. Here, we cloned the human K6a promoter, and using a cell-based reporter gene assay, a
chemical library was screened for K6a inhibitors. One compound, compactin, the precursor of all cholesterol-
lowering statins, was of particular interest. We found that, surprisingly, simvastatin and other statins inhibit K6a
promoter activity and K6a protein expression. Further investigation showed that this effect works through
cholesterol/mevalonate pathway inhibition rather than an off-target effect. Inhibition of both basal and IFN-g-
inducible K6a expression by statins was demonstrated. Both these K6a inhibitory effects were found to be
mediated by Stat1 transcription factor, but only the IFN-g-inducible promoter activity was controlled via the Stat/
JAK pathway. The repressive effect of statins was found to be mediated by the isoprenoid pathway downstream
of mevalonate (the intermediate following 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) but upstream of
cholesterol, specifically the geranylgeranylation pathway. These data set the scene for further unraveling
signaling pathways that control the K6a promoter, as well as facilitating clinical trials for statins in PC patients.
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INTRODUCTION
Pachyonychia congenita (PC) is a highly debilitating
keratinizing disorder caused by mutations in any one of four
keratin genes KRT6A, KRT6B, KRT16, or KRT17 (Bowden
et al., 1995; McLean et al., 1995; Smith et al., 1998). The
phenotypic and mutational spectrum found in PC is reported
by Wilson et al., 2011. For PC patients, the most painful,
disabling feature is focal plantar keratoderma (Leachman
et al., 2005; Liao et al., 2007).
Currently, there are no specific therapies for PC but several
research groups are actively working on the development of
therapeutics (Kaspar et al., 2011), in particular using small
interfering RNA (siRNA) to inhibit production of the mutant
keratin (Hickerson et al., 2006, 2008; Leachman et al., 2008;
Smith et al., 2008). This preclinical work recently led to the
first proof-of-concept siRNA clinical trial in the field of
dermatology, where a PC patient was treated by intradermal
injection of a mutation-specific siRNA (Leachman et al., 2010).
However, intradermal injection proved to be very painful and
unsuitable for routine use. Hickerson et al., 2011, report a
promising chemical approach to cutaneous siRNA delivery;
however, this is still a long way from clinical application.
An alternative approach is to try to develop pharmaco-
logical therapy for PC. Here, the problem of delivery is more
tractable, as small-molecule drugs (typically o550Da) may
be used systemically, or with suitable formulation and/or
chemical modification, applied topically. However, the
biggest hurdle for development of small-molecule therapy
for an uncommon inherited disorder such as PC is the
extremely high cost of drug development, typically hundreds
of millions of dollars (Dickson and Gagnon, 2004; Kaspar,
2005). Currently, the only drugs available to treat hyperker-
atotic disorders such as PC are retinoids, which act via
retinoic acid response elements (RAREs) present in the gene
promoters of many keratins and other structural molecules of
the epidermis to repress gene expression (de The et al., 1990).
These molecules are therefore not very specific for a given
keratin or keratin-related gene, and their overall effect is to
non-specifically inhibit epidermal differentiation. For this
reason, retinoids are not well tolerated in keratinizing
disorders because, although they reduce hyperkeratosis, they
thin the epidermis and lead to blistering, as well as a range of
other side-effects (DiGiovanna, 2010; Ormerod et al., 2010).
From the International Pachyonychia Congenita Research
Registry data, the major PC gene is KRT6A, where about
50% of patients in the registry carry mutations (Smith et al.,
this issue). Interestingly, the four keratin genes involved
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in PC differ from other keratins associated with human
genetic disorders because they are regulated in both an
inducible and constitutive manner. The inducible component
includes induction during UV light exposure, wound healing,
viral infections, psoriasis, cancer, and other challenges
to epithelial tissues (Bernerd et al., 1993; Moll et al., 1994;
Komine et al., 2001; Hattori et al., 2002; Wakabayashi et al.,
2003; Endo et al., 2008). Such naturally occurring induction
and repression mechanisms led us to hypothesize that certain
small molecules may exist that can interfere with this natural
induction/repression machinery and thereby modulate the
expression of these inducible keratins. The proximal promo-
ter of human keratin 6 (K6) has been studied previously using
a clone originally derived from the KRT6B promoter
(Ma et al., 1997). It has been shown that the KRT6B
expression is strongly upregulated by IFN-g and down-
regulated by retinoic acid through IFN-g activation sites and
RAREs in the promoter (Tomic-Canic et al., 1996; Freedberg
et al., 2001; Hattori et al., 2002). Through studies of the
Keap1/Nrf2 pathway involved in activation of detoxification
enzymes such as ketoreductase (Nioi et al., 2003), it has
emerged that the stress-inducible keratins such as K6 can be
activated by chemicals, such as sulforaphane (Wakabayashi
et al., 2003; Kerns et al., 2007), that induce gene expression
via antioxidant response elements. Bioinformatics analysis
of the human KRT6A promoter sequence revealed that this
indeed contains RAREs, IFN-g activation site elements,
and antioxidant response elements (Table 1; Figure 1a); and
hence, one would predict that activity of this promoter
should be induced by IFN-g and sulforaphane, and inhibited
by retinoic acid. Thus, these compounds represent a good
starting point to validate a high-throughput chemical library-
screening assay based on the KRT6A promoter.
One approach to development of new drugs for use in PC
or other rare disorders is to screen molecules already
approved for human use, in the hope that an existing drug
may have a beneficial effect for a new, undiscovered disease
indication. This is a high-risk but low-cost approach to
finding new drugs to treat rare disorders. Here, we describe
such a small-molecule-screening campaign aimed at identi-
fying compounds to inhibit K6a gene/protein expression, as
possible means of increasing the pharmacological repertoire
for treatment of PC. Unexpectedly, we found that members of
the statin family of cholesterol-lowering drugs are able to
inhibit human KRT6A promoter activity.
RESULTS
The KRT6A promoter responds as predicted to known
inducers/inhibitors
A 6,058-bp fragment comprising the promoter region of the
human KRT6A gene, extending to the transcriptional start site
of the gene, was generated by PCR cloning (Figure 1a).
Bioinformatics analysis showed that this promoter contains a
single RARE site close to the cap site, as well as three
antioxidant response and seven IFN-g activation site elements
scattered throughout the 6 kb promoter fragment (Figure 1a;
Table 1). By transient transfection, the KRT6A-promoter-
driven firefly luciferase construct (hereafter described as
‘‘K6a-luciferase’’ for brevity) was expressed in the strain of
HaCaT cells in use in our laboratory, which we had
previously found by RT-PCR, DNA sequencing, and quanti-
tative real-time RT-PCR to express only K6a but not K6b or
K6c (data not shown). In all transfections, a standard trace
amount of cytomegalovirus (CMV) promoter-driven Renilla
luciferase was cotransfected to act as an internal control for
cell viability and transfection efficiency. Preliminary transient
transfection experiments showed that K6a-luciferase is active
in HaCaT cells and primary keratinocytes but shows
negligible expression in fibroblasts (data not shown).
Figure 1b shows the K6-luciferase activity in HaCaT cells,
after normalization against the Renilla luciferase signal in
untreated cells and cells treated with IFN-g, sulforaphane,
and retinoic acid, at concentrations commonly used in the
literature. As expected from studies of the K6b promoter and
presence of seven IFN-g activation site elements in the
promoter, treatment with 100Uml1 IFN-g strongly induced
K6a-luciferase expression by approximately 3-fold. Similarly,
10 mM sulforaphane induced K6a-luciferase expression
by approximately 2-fold, consistent with the antioxidant
response elements present in the promoter. In contrast, 1 mM
retinoic acid inhibited K6a-luciferase expression by B50%,
consistent with the RAREs present in the promoter. All three
agents showed dose-dependent responses (data not shown).
Table 1. Regulatory elements in the human K6a
promoter
Site Sequence (50–30)
ARE consensus RTKAYNNNGCR
K6a ARE1 (1473) CTGAGTTAGCA
K6a ARE2 (4420) TTGAAGTGGCA
K6a ARE3 (4900) ATGAACATGCG
GAS consensus TTCNNNKAA
K6a GAS1 (309) TTCAGTGAA
K6a GAS2 (1582) TTCCCAGAA
K6a GAS3 (2038) TTCAATTAA
K6a GAS4 (4904) TTATATGAA
K6a GAS5 (5711) TTCCCTGAA
K6a GAS6 (5864) TTCCAGGAA
K6a GAS7 (6054) TTCCCTGAA
RARE consensus (half site) AGGTCA
K6a RARE (139) AGCTCACCTTAGGACTGGG
Abbreviations: ARE, antioxidant response element; GAS, IFN-g activation
site; RARE, retinoic acid response element.
Note: numbering refers to base pairs upstream of the K6a transcriptional
start site (http://genome.ucsc.edu; gene symbol KRT6A).
R=A/G; K=G/T; Y=C/T; N=A/G/C/T.
ARE consensus derived from Erickson et al, 2002; GAS consensus
sequence from Kanno et al, 1993; Decker et al, 1997; and Contursi et al,
2000; and RARE consensus sequence from Perlmann et al, 1993;
Radoja, 1997; and Umesono et al, 1991.
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Thus, the K6a-luciferase construct appeared to behave as
expected based on predicted inducers/repressors. For con-
venience and reproducibility in a high-throughput-screening
context, a stable HaCaT clone was generated via puromycin
selection. A clone showing good levels of constitutive
K6a-luciferase expression that responded in an identical
manner to these agents, as described above (Figure 1b), was
chosen for chemical library screening (data not shown).
Small-molecule library screening identified nine confirmed
inhibitors of KRT6A
The chemical library chosen for screening was the National
Cancer Institute (NCI) 2,522 diversity set, which consists of
2,522 small drug-like chemical compounds. After initial
screening of all compounds at a concentration of 20 mM,
110 compounds were found that decreased K6a-luciferase
expression by 40% compared with untreated controls. Of
these, 59 compounds decreased K6a-luciferase activity by
450% after normalization to Renilla luciferase expression. In
addition, 61 compounds increased K6a promoter activity
by B50% after normalization, which were not considered
further here. An additional 146 compounds up- or down-
regulated K6a promoter activity but were found to have
cytotoxic effects, and therefore were discarded from subse-
quent analysis. All hit compounds were retested in triplicate
using the K6a-luciferase assay and were also counterscreened
against a CMV-driven luciferase construct to eliminate false
positives, such as inhibitors of luciferase enzymatic activity,
rather than K6a promoter activity or general inhibitors of
transcription/translation. Following counterscreening and hit
validation, nine confirmed hits remained that inhibited K6a
promoter activity by 450%, as exemplified in Figure 2a. An
independent sample of all these compounds was sourced and
in all cases, the activity was retained, further validating these
hit compounds (data not shown). Of these, eight were
chemical structures that were not closely related to known
drugs and are not discussed further here; however, one of
the validated hits, compactin (Brown et al., 1978), is the
precursor of the cholesterol-lowering statin class of drugs
currently in widespread clinical use (Miller, 1999).
Statins inhibit KRT6A basal and inducible promoter activity
As shown in Figure 2b, simvastatin was able to inhibit K6a-
luciferase activity to a similar degree to the initial validated
hit compound, compactin. The level of inhibition of the K6a-
luciferase reporter was also similar to that seen with retinoic
acid (Figure 1b). Figure 2c shows the effect of simvastatin on
actual K6a protein expression in HaCat cells by western
blotting. K6a protein expression was reduced compared with
DMSO (vehicle) control, but the effect was less marked than
with 1 mM retinoic acid (Figure 2c). In a separate experiment,
quantification of western blots was performed using the Li-Cor
Odyssey infrared imaging system (Li-Cor, Cambridge, UK).
Specifically, K6a protein expression, normalized against an
internal actin standard, was substantially inhibited in a dose-
dependent and time-dependent manner (Figure 2c). Importantly,
we did not observe inhibition of K5 or K14 by western blotting
(data not shown), indicating that the inhibitory effect has
some degree of specificity. Other statins tested included
pravastatin, fluvastatin, lovastatin, and mevastatin, all of
which inhibited K6a promoter activity in a similar manner
(data not shown). Thus, it appeared that, unexpectedly,
statins are somehow able to inhibit expression of the K6a
promoter (Figure 2a and b), which was confirmed at the level
of protein expression (Figure 2c and d). For simplicity,
simvastatin was employed in all subsequent experiments
described here, although very similar effects were seen with
other statins (data not shown).
To investigate whether the inhibitory effect of statins was
limited to the basal K6a promoter activity or whether statins
are also able inhibit inducible expression, simvastatin was
used in combination with IFN-g. Two concentrations of IFN-g
(25 and 50Uml1) were shown to upregulate K6a-luciferase
in a dose-dependent manner (Figure 3); however, in the
presence of simvastatin, not only was this induction
completely abolished but also, in addition, K6a-luciferase
was reduced to well below the basal expression level. Thus,
statins appear to fully block the inducible expression of the
K6a promoter as well as its basal activity.
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Figure 1. K6a promoter elements and activities. (a) The human K6a promoter.
Schematic of the human KRT6A promoter (6,058bp) with recognized elements
annotated (Table 1). (b) The K6a promoter responds to predicted inducers or
inhibitors. HaCaT cells were transiently transfected with the K6a-luciferase
construct and cytomegalovirus-Renilla luciferase. The resultant luciferase data
obtained at 24hours posttransfection were normalized against Renilla and the
untreated cells set to 100% (K6a-luc bar). In all, 100Uml1 IFN-g resulted in an
approximately 3-fold increase in K6a-luciferase, and 10mM sulforaphane resulted
in an approximately 2-fold increase in K6a expression, whereas 1 mM retinoic
acid treatment reduced K6a expression by B50%. Error bars represent
standard error of the mean derived from assay replicates. ARE, antioxidant
response element; GAS, IFN-g activation site; K, keratin; KRT, keratin gene;
K6a-luciferase, KRT6A-promoter-driven firefly luciferase; luc, luciferase;
RA, retinoic acid; RARE, retinoic acid response element; Sul, sulforaphane.
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Inhibition of KRT6A by statins is mediated by the cholesterol
pathway
Statins act by competitively inhibiting the enzyme HMG
CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase),
which is the rate-limiting step in cholesterol biosynthesis, and
therefore the prime target for anti-cholesterol therapy
(Russell, 1992). A schematic illustrating key features of the
cholesterol biosynthesis pathway is shown in Supplementary
Figure 1. To determine whether inhibition of K6a promoter
activity was due to the effect of statins on inhibiting the
cholesterol biosynthetic pathway rather than an off-target
effect, e.g., binding directly to a transcription factor involved
in control of the K6a promoter, the intermediate in the
cholesterol pathway downstream of 3-hydroxy-3-methyl-
glutaryl-CoA reductase, mevalonate (Russell, 1992), was
used to see whether this could rescue K6a promoter activity.
Figure 4 shows that addition of mevalonate alone has no
appreciable effect on the constitutive expression level of the
K6a-luciferase construct. In contrast, mevalonate is able to
rescue the inhibition of K6a-luciferase by simvastatin
(Figure 4). Furthermore, mevalonate is able to rescue
simvastatin’s inhibition of K6a induction by IFN-g (Figure 4).
In contrast, addition of cholesterol had no effect on basal K6a
promoter activity in the presence or absence of simvastatin,
plus or minus IFN-g (data not shown). Overall, these data
suggest that the effect of statins on K6a promoter activity is in
fact due to inhibition of the mevalonate/cholesterol biosyn-
thetic pathway rather than via an off-target mechanism.
The fact that mevalonate, but not cholesterol, can rescue the
effects of simvastatin implies that the key determinant in this
K6a inhibitory mechanism is a molecule downstream of
mevalonate but upstream of cholesterol in this biosynthetic
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Figure 2. Small-molecule library screening identified statins as K6a inhibitors. (a) K6a-luciferase expression data were normalized as described in Figure 2.
Compared with untreated cells (K6a-luc), a significant library hit that reproducibly inhibited K6a-luciferase expression by B50% was compactin. (b) As
compactin is the precursor from which all cholesterol-lowering statins are synthesized, we tested a number of statins for K6a inhibitory effects. As shown here,
SS reduced K6a-luciferase expression by 450% compared with untreated cells (K6a-luc). Error bars represent standard error of the mean derived from assay
replicates. (c) Western blotting showed that 24 hours incubation with SS (8 mM) reduces K6a protein expression in HaCat cells compared with mock (DMSO)-
treated cells. In all, 1mM RA was used as a positive control. The blot was reprobed with GAPDH as a loading control. No appreciable effect of SS on K5 or K14
expression was observed (data not shown). (d) In an experiment separate from that of c, above, infrared imaging (Li-Cor Odyssey system) was used to quantify
K6a protein expression on western blots, normalizing against an internal actin-loading control. Over a time course of 24–72 hours, SS was seen to inhibit
K6a protein expression at both 1 and 8 mM concentrations. The equivalent quantity of DMSO (used to deliver SS) was used as a negative control. Note that
the 1 and 8 mM SS samples were run on the same gel but in non-consecutive lanes (as denoted by the bar). GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
K, keratin; KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase; RA, retinoic acid; SS, simvastatin.
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Figure 3. Statins inhibit both constitutive and IFN-inducible K6a expression.
K6a-luciferase expression data were normalized as described in Figure 2.
Again, SS (10 mM) reduced K6a-luciferase activity by 450% compared with
untreated cells (K6a-luc). Two different doses of IFN-g (25 and 50Uml1)
strongly induced K6a expression in a dose-dependent manner; however,
addition of 10 mM SS in addition to IFN-g (SSþ IFN 25U; SSþ IFN 50U) not
only blocked the 2- to 3-fold induction observed but also reduced K6a-
luciferase expression below the basal level (K6a-luc). Thus, statins inhibit both
the constitutive and inducible expression of the K6a promoter. Error bars
represent standard error of the mean derived from assay replicates. K, keratin;
KRT, keratin gene; K6a-luciferase, KRT6A-promoter-driven firefly luciferase;
luc, luciferase; SS, simvastatin.
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pathway. The most obvious candidates are components of the
isoprenylation pathways, which are important posttransla-
tional modifications of G-proteins, which in turn are key
signaling molecules.
Effect of statins on KRT6A activity is mediated by isoprenylation
The two main isoprenoid modifications of proteins are
farnesylation (mediated by farnesyl pyrophosphate, FPP, by
the activity of farnesyl transferase) and geranylgeranylation
(mediated by geranylgeranyl pyrophosphate, GGPP, through
the action of geranylgeranyl transferase), as reviewed
(Russell, 1992; McTaggart, 2006) and shown in Supplemen-
tary Figure 1. To see whether either of these pathways down-
stream of mevalonate was involved in the K6a inhibitory
effect of statins, we added FPP or GGPP to the K6a-luciferase
assay to see if these could rescue the inhibition. FPP was
unable to rescue simvastatin’s inhibition of basal and IFN-g-
induced K6a promoter activity (data not shown); however,
GGPP was able to rescue the effect of simvastatin on K6a
(Figure 5). These data implicate geranylgeranylation as a key
factor in the downregulation of K6a promoter by statins.
KRT6A inhibition by statins depends on Stat1 transcription factor
It has been reported that statins exhibit an anti-inflammatory
effects in addition to their cholesterol-lowering effects
(Abeles and Pillinger, 2006; Smaldone et al., 2009).
Specifically, it has been shown that the induction of certain
lymphocyte-specific genes such as CD40 by IFN-g can be
blocked by statins. Furthermore, JAK/STAT signaling is an
important pathway involved in IFN-g signal transduction
(Gough et al., 2008), where inhibition of CD40 by statins has
been shown to be dependent on the Stat1 transcription factor
(Lee et al., 2007). To investigate whether Stat1 is involved in
inhibition of the K6a promoter by statins, we employed a
proprietary, validated siRNA against Stat1 to see whether this,
like statins, also inhibits K6a promoter activity. Western
blotting with a Stat1 monoclonal antibody confirmed (i) that
Stat1 is normally expressed in HaCaT cells and (ii) that the
siRNA is highly efficacious in knocking Stat1 protein levels
down to o20% (data not shown). In HaCaT cells, Stat1-
specific siRNA was shown to inhibit K6a-luciferase expres-
sion in a dose-dependent fashion (Figure 6). Moreover, use of
both simvastatin and Stat1 siRNA showed a synergistic
inhibition of K6a-luciferase activity (Figure 6), consistent
with inhibition of Stat1 by two independent mechanisms, i.e.,
degradation of Stat1 mRNA by siRNA and inhibition of Stat1
gene expression by statins via an unknown pathway.
DISCUSSION
Overall, the data presented here show that a cholesterol-
lowering family of drugs, the statins, can inhibit expression of
both basal and IFN-g-inducible activity of the keratin K6a
promoter. Importantly, K6a inhibition was confirmed at the
protein level (Figure 2c and d). The precise pathways
whereby statins inhibit K6a remain unknown, but here, we
have gained some preliminary mechanistic insights through
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Figure 5. The inhibitory effect of statins on the K6a promoter acts via the
geranylgeranylation pathway. K6a-luciferase expression data were
normalized as described in Figure 2. Again, SS (10 mM) can be seen to reduce
K6a-luciferase activity by450% compared with untreated cells (K6a-luc). To
investigate which, if any, isoprenoid species downstream of mevalonate was
involved in the inhibitory effect of statins on K6a, key intermediates were used
to attempt rescue. Addition of 1 mM GGPP alone had little effect on K6a-
luciferase expression; however, GGPP completely rescued the reduction in
K6a expression mediated by simvastatin (SSþGGPP). Likewise, GGPP
rescued IFN-g induction of K6a expression (SSþ IFNþGGPP). Error bars
represent standard error of the mean derived from assay replicates. GGPP,
geranylgeranyl pyrophosphate; K, keratin; KRT, keratin gene; K6a-luciferase,
KRT6A-promoter-driven firefly luciferase; luc, luciferase; SS, simvastatin.
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the use of siRNA against candidate genes, rescue of
expression using pathway intermediates and specific kinase
inhibitors. Our data clearly show that the inhibitory effects
of statins on K6a are dependent on Stat1 transcription factor.
Interestingly, a similar inhibitory effect has been shown
in lymphocytes for another IFN-g-inducible gene, CD40
(Lee et al., 2007).
We have shown that the K6a inhibitory effect of statins is
due bona fide inhibition of the cholesterol/mevalonate
biosynthesis pathway rather than an off-target effect (Figure 4),
and interestingly, that this effect can be rescued by
mevalonate but not cholesterol itself. Mevalonate is a key
molecule in biosynthesis of the isoprenoids, the farnesyl and
geranylgeranyl groups added to many G-proteins posttransla-
tionally, such as members of the Rho and Ras families of
small guanosine triphosphate-binding proteins, which are key
signaling molecules and prime suspects in the immuno-
modulatory effects of statins (Smaldone et al., 2009). Our data
strongly suggest that it is the geranylgeranylation pathway
rather than the farnesylation pathway that is responsible
because GGPP (Figure 5) can rescue K6a promoter inhibition
by statins, but not FPP (McTaggart, 2006).
Only in recent years, through the availability of both
commercial and non-profit chemical compound libraries
(such as the free NCI library used here), coupled with the
increased availability of robotics suitable for high-throughout
screening, has the advent of drug discovery been seen in an
academic context, outside of the biopharmaceutical industry.
Our study illustrates two key outcomes of academic drug
discovery. First, fresh insights have been gained into the
signaling pathways that control keratin expression. As there
was no previous obvious clue that keratin gene expression
was in any way dependent upon the cholesterol biosynthetic
pathway, this somewhat surprising result opens up a
new avenue for research into the control of keratin gene
expression. Second, and importantly, we have identified an
already approved, widely used, and inexpensive drug that
might prove to be of use in a neglected inherited skin disorder
or group of disorders, immediately opening up the possibility
of clinical trials. This circumvents the hundreds of millions of
dollars required to develop a drug from scratch, which is
unfeasible in an ultra-rare disorder. Because of the rarity of PC
and related keratinizing disorders, a chemical library screen
based on a simple reporter gene promoter assay is something
which the profit-driven pharmaceutical industry is likely to
have considered to be too high risk in relation to potential
return on the investment; however, this makes an ideal
academic drug discovery project. In the future, it is likely that
there will be closer collaboration between academia and
industry in drug development (Vallance et al., 2010).
We are continuing our efforts to elucidate the precise
mechanism whereby statins inhibit K6a gene expression.
However, given the excellent safety profile of statins, we are
already involved in open-label clinical trials, with recruitment of
a small case series of mutation-defined PC patients identified
through the International Pachyonychia Congenita Research
Registry. These trials will make use of both systemic and
topically formulated statins. While it is highly unlikely that
statins will show complete specificity for keratins, their general
anti-inflammatory effects might also be useful in inhibiting the
process of hyperkeratosis, whose underlying pathomechanisms
remain poorly understood, but is thought to involve inflamma-
tory factors such as tumor necrosis factor-a. Even if only
partially effective, the use of statins in the treatment-keratinizing
disorders such as PC might complement other broad-spectrum
drugs such as retinoids. It is also possible that a combination
therapy of low-dose systemic or topical retinoids, supplemented
by statins, may prove to be more effective.
In conclusion, we have identified statins as potential K6a
inhibitory drugs, facilitating a range of low-cost, safe clinical
trials in the orphan disease PC.
MATERIALS AND METHODS
Promoter constructs
A 6,058 bp DNA fragment comprising the KRT6A promoter
sequence upstream of, and including the transcription start site,
was generated from genomic DNA of a normal, healthy control
individual using primers PRM3.L (50-TTCCTAGCCATGTTGTGTGT
TC-30) and PRM3.R (50-GAGGGAAGAGAAGCAGGACTAG-30). This
fragment was cloned into plasmid pCR2.1 (Invitrogen, Paisley, UK)
and fully sequenced. The full-length insert from a sequence-verified
clone was subcloned into the pGL4.21 promoterless vector contain-
ing a humanized, high-turnover firefly luciferase gene (luc2P ;
Promega, Southampton, UK) using KpnI and XhoI. A control plasmid
was generated by subcloning the CMV promoter (BamHI/BglII
fragment) from pcDNA3 (Invitrogen) into pGL4.21 (BamHI site). The
pRL-CMV plasmid (Renilla luciferase driven by the CMV promoter)
was obtained from Promega.
Cell lines
The HaCaT cell line was obtained from Professor Birgit Lane’s Laboratory,
School of Life Sciences, University of Dundee, UK, originally derived
from human adult skin keratinocytes (Boukamp et al., 1988). HaCaT cells
were maintained in Gibco DMEM (Invitrogen, Paisley, UK) supplemented
with 10% keratinocytes, Gibco) at 37 1C with a 5% CO2 atmosphere.
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Figure 6. Stat1 transcription factor, known to be involved in IFN-c signaling,
is linked to K6a expression. Stat1 has been linked to expression of IFN-g-
inducible genes in lymphocytes, e.g., CD40. To see whether Stat1 was linked
to K6a expression, we used a specific siRNA for Stat1. K6a expression was
inhibited by Stat1 siRNA in a dose-dependent manner (siRNA 7–67nM). When
SS was used in combination with the Stat1 siRNA, the dose-dependent
inhibitory effect increased. It has been suggested that statins inhibit expression
of Stat1 via an unknown pathway (Lee et al., 2007). Our data are consistent
with this, as action of statins at the transcriptional level synergizes with
degradation of the Stat1 mRNA. Error bars represent standard error of the
mean. K, keratin; siRNA, small interfering RNA; SS, simvastatin.
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Transfection
For transient transfection of HaCaT or fibroblasts, cells were plated
in 96-well plates at a density ofB1 104 cells per well in 100ml of
DMEM with 10% fetal calf serum 24hours before transfection. These
conditions routinely gave 70% confluency at the time of transfec-
tion. In all, 0.05 mg of plasmid DNA, with or without 0.005 mg pRL-
CMV Renilla plasmid, was complexed with 0.15 ml Fugene 6 (Roche,
West Sussex, UK) in 4.85 ml of DMEM with no fetal calf serum or
antibiotics. DNA–Fugene 6 complexes were mixed gently and incubated
at room temperature for 20minutes before adding to cells. For stable
transfection, HaCaT cells were transfected with linearized plasmid
(KRT6A promoter in pGL4.21, above) in 10 cm dishes using a scaled-
up version of the transfection protocol and clones selected using
1mgml1 puromycin (Sigma-Aldrich, Poole, UK).
Dual-luciferase reporter assay system
At 24 hours after transfection, medium was removed and cells in
96-well plates were rinsed in phosphate-buffered saline solution
(Invitrogen). Cells were lysed in 20 ml 1 luciferase lysis buffer
(Dual-Luciferase Reporter Assay System, Promega) at room tem-
perature for 15min. Both firefly and Renilla luciferase activities
were measured by LUMI Star OPTIMA luminometer (BMG Labtech,
Aylesbury, UK) according to manufacturer’s protocol.
Western blotting
Total protein extracts of HaCat cells were subjected to Coomassie
blue staining and western blotting, as described previously (Smith
et al., 2008). Keratin expression was detected by immunoblotting
using 1 hour incubations of the following primary antibodies: 1:200
dilution anti-K6 (Ks6.KA12; Progen Biotechnik, GmbH, Heidelberg,
Germany); 1:1,000 anti-K14 (LL001); and 1:10,000 dilution anti-K5
(BL18). All antibodies were kindly donated by EB Lane, College of
Life Sciences, University of Dundee, Dundee, UK. On western blots,
protein bands were either subjected to enhanced chemilumin-
secence staining or, alternatively, were detected and quantified
using a Li-Cor Odyssey infrared protein imager according to the
manufacturer’s recommended protocols (Li-Cor, Cambridge, UK),
and data normalized against an internal actin standard.
Reagents
The NCI 2,522 chemical library was obtained from the NCI,
National Institutes of Health, Bethesda, MD. IFN-g, simvastatin,
pravastatin, fluvastatin, lovastatin, and mevastatin were purchased
from Calbiochem (San Diego, CA). Retinoic acid, DL-mevalonate,
cholesterol, GGPP, and FPP were obtained from Sigma-Aldrich.
Sulforaphane was kindly provided by Professor John Hayes (Nine-
wells Medical School, Dundee, UK). Stat1 siRNA and antibody were
purchased from Cell Signaling Technology (Beverly, MA).
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